PROKIDNEY CORP. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PROKIDNEY CORP. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($68.99M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($61.19M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | ($35.47M) | Mar 18, 2026 |
| FY2022 | Dec 31, 2022 | ($54.50M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2021 | ($2.32M) | Mar 24, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($165.01M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($183.68M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | ($151.52M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | ($153.01M) | Mar 17, 2025 |
| FY2021 | Dec 31, 2021 | ($2.33M) | Mar 24, 2022 |
| FY2022 | Dec 31, 2020 | ($27.02M) | Mar 28, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.12M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $127.67M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $106.71M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $82.07M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $46.26M | Mar 22, 2024 |
| FY2022 | Dec 31, 2020 | $21.04M | Mar 28, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($120.12M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($126.35M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | ($90.07M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | ($77.09M) | Mar 17, 2025 |
| FY2021 | Dec 31, 2021 | ($1.21M) | Mar 24, 2022 |
| FY2022 | Dec 31, 2020 | ($25.18M) | Mar 28, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.20M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $29.51M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $34.20M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $1.85M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $5.19M | Mar 22, 2024 |
| FY2022 | Dec 31, 2020 | $5.46M | Mar 28, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $335.57M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $441.07M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $420.55M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $518.00M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $40.30M | Mar 28, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.78M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $39.44M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $29.22M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $13.06M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $13.38M | Mar 28, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.01B) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($994.95M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | ($1.10B) | Mar 18, 2026 |
| FY2025 | Dec 31, 2022 | ($1.10B) | Mar 18, 2026 |
| FY2024 | Dec 31, 2021 | $26.92M | Mar 17, 2025 |
| FY2021 | Feb 24, 2021 | $0 | Mar 24, 2022 |
| FY2023 | Dec 31, 2020 | $9.86M | Mar 22, 2024 |
| FY2022 | Dec 31, 2019 | $15.88M | Mar 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.27B) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($1.20B) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($1.14B) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.10B) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($161.51M) | Mar 28, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.54M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $99.12M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $60.65M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $490.25M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $20.56M | Mar 28, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Mar 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Mar 28, 2023 |